TODAY'S HEADLINES

FDA makes sweeping changes for opioids

After receiving pressure from Congress, FDA makes sweeping changes to its opioids policy, including increasing availability of abuse-deterrent formulations. Read more

Insurers set performance-based price for heart drug

In one of the few arrangements of its kind, Cigna and Aetna set a performance-based price for this new heart drug. Read more

CONTINUING PHARMACY EDUCATION

Part 1: Recognition and referral to enhance recovery: The pharmacist's role in managing opioid use disorder

This month's CE activity is open for pharmacists and pharmacy technicians, "Part 1: Recognition and referral to enhance recovery: The pharmacist's role in managing opioid use disorder." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

FDA clears long-acting ADHD drug

FDA approved a long-acting, orally disintegrating tablet for ADHD that is bioequivalent to Adderall XR. Details

February 12, 2016

Related Articles

Blog: Use and abuse of opioids: FDA responds

Hearing ups pressure on drugmakers' prices